Skip to main content
Premium Trial:

Request an Annual Quote

NanoString, Brigham and Women's Hospital Collaborate on Genomics-based Cancer Diagnostics

NEW YORK (GenomeWeb) – NanoString Technologies announced after the close of the market on Monday a collaboration with Brigham and Women's Hospital aimed at accelerating genomic biomarker discoveries into clinical cancer diagnostics.

Leveraging NanoString's Elements reagents for use on the company's nCounter platform, the partners will develop assays to detect gene expression, copy number variations, and fusions from various tumor samples, NanoString said. Brigham and Women's researchers will evaluate and analyze a repository of patient-derived tumor tissues to identify gene signatures and gene expression profiles that typify a specific tumor type. NanoString said the work is expected to hasten the development of validated diagnostic tests that could improve clinical decisions made in the treatment of cancer patients.

NanoString will have the right to license diagnostic content developed resulting from the collaboration. Further financial and other terms were not disclosed.

"This collaboration is designed to support not only the discovery of the underlying biology of cancer, but the rapid development of clinical tests," Jeffrey Golden, chairman of Brigham and Women's pathology department, said in a statement. "Together we believe we will improve our ability to diagnose, provide better prognostication, improve treatment stratification including qualifications for clinical trials, and conduct biomarker discovery and validation."

Scott Rodig is the lead investigator at the hospital on the project and is joined by Brigham and Women's colleagues Deborah Dillon, Jon Aster, Michael Kluk, and Neal Lindeman.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.